Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
39 hedge funds and large institutions have $153M invested in Carisma Therapeutics in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
22% more funds holding
Funds holding: 32 → 39 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $185M → $153M (-$32.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.63M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.78M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.11M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$928K |
| 5 |
Bank of New York Mellon
New York
|
+$486K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$812K |
| 3 |
JP Morgan Chase
New York
|
-$760K |
| 4 |
TG
TCW Group
Los Angeles,
California
|
-$693K |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$597K |
CARM Hedge Fund Activity: Q2 2014 in Review
39 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2014, worth a combined $153M — down 17% from $185M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CARM positions and 5 closed out — a net gain of 8 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.63M. The largest seller was BlackRock Advisors, cutting an estimated $1.1M.
- 39 institutional investors held Carisma Therapeutics (CARM) as of Q2 2014, up from 32 in Q1 2014.
- Funds reported $153M of Carisma Therapeutics stock for Q2 2014, down 17% quarter-over-quarter.
- 13 funds opened new Carisma Therapeutics positions in Q2 2014 and 5 closed out, a net change of +8 holders.
- The largest Carisma Therapeutics buyer in Q2 2014 was Fidelity Investments, an estimated $2.63M added.
- The largest Carisma Therapeutics seller in Q2 2014 was BlackRock Advisors, an estimated $1.1M sold.
Based on aggregated 13F filings for Q2 2014.